Deciding Whether to Start a Third or Fourth Line of Treatment — An Honest Framework

Sometimes — but the honest answer is that expected benefit narrows with each successive line. A third or fourth line is more likely to help when your day-to-day function is still good, when a genuinely different treatment option exists, and when the goal is clear. When those are missing, choosing not to start another line is an equally valid decision.

This page is written for the point at which the second or third line has stopped working and someone has to decide what happens next. It does not push you toward treating and it does not push you toward stopping. It sets out what benefit realistically looks like this far along, what the decision actually costs, and how other families work through it — including the families who conclude that another line is not the right use of the time they have.

Nothing here is a recommendation for your own situation. Later-line decisions depend on your cancer type, what you have already received, your current fitness and your own stated wishes — all of which your treating oncologist has in front of them and this page does not.

Smaller than the line before it. Response rates generally fall with each successive line of systemic treatment, and the proportion of patients who benefit from a third or fourth line is lower than in the first or second. That does not make a later line pointless. It makes it a decision that deserves specific numbers rather than general hope.

Ask for the range that applies to you. Response rates are published as ranges by guideline bodies such as NCCN, ASCO and ESMO, and those ranges are specific to cancer type, biomarker status and line of therapy. A figure quoted for first-line use in one cancer tells you very little about a fourth-line decision in another. Ask your oncologist to say which range applies to your case, and to say plainly when the evidence for that line is thin.

Ask what the treatment is intended to do. Three different intentions get discussed in the same breath: shrinking the disease, holding it steady, and relieving one specific symptom. They are judged on different endpoints. A treatment given mainly to ease breathlessness or pain should be assessed on whether that symptom improves within a defined period, not only on what the next scan shows.

Day-to-day function does most of the work. How much of the day a patient spends up and about, rather than resting, changes both eligibility for a later line and how well it is tolerated. Oncologists record this as performance status. Ask directly where you currently sit on that scale, what it means for the options in front of you, and what would happen to the plan if it changed.

Treat any source that answers this question with a single percentage with caution, and be equally careful with language that promises more than later-line evidence supports. Immunotherapy in particular attracts more hopeful vocabulary than the later-line data behind it can carry.

• The drug or regimen itself — varies by molecule and by whether a biosimilar version is marketed in India. Ask for the per-cycle figure and the number of cycles currently planned, not a single total.
• Day-care administration — immunotherapy is given as day care at CION centres. Ask what chair, nursing and pharmacy charges add to each visit, because these recur every cycle.
• Pre-cycle blood tests — routine before most cycles, and often expanded if a side effect is being monitored. Small individually, meaningful across a course.
• Response-assessment imaging — PET-CT for response assessment is coordinated at partner imaging centres rather than provided in-house, so it is billed separately and sits outside the treatment quote entirely.
• Managing side effects — immune-related reactions can require steroids, extra reviews or admission. This is rarely included in a base estimate and is worth asking about explicitly.
• Scheme and insurance coverage — ArogyaSri, CGHS and cashless policies apply ceilings and may treat later lines differently from earlier ones. Get coverage for this line confirmed in writing before the first cycle, not after it.
• The costs nobody bills you for — travel to and from the centre, time away from work for both patient and caretaker, and paid help at home. Families routinely underestimate these, and at a third or fourth line they run for months.

If a centre will not give you an indicative written estimate before you start, that is itself information. Ask again, and ask a second centre.

Alongside treatment, not after it. Palliative care is symptom-focused care — pain, breathlessness, appetite, sleep, and the family's own load — and it runs in parallel with anti-cancer treatment. Asking for it does not withdraw your treatment and does not mean a decision to stop has already been taken.

The misunderstanding is common and it costs families a great deal. Many hear the word “palliative” and hear “the end”, so the referral gets refused, and symptom support that could have started months earlier arrives in a hurry at the worst possible moment. Guideline bodies including ASCO recommend introducing palliative care alongside standard oncology care for people with advanced cancer, not only at the very end. A referral at the point where a third line is being discussed is ordinary practice, not a signal about how much time anyone thinks is left.

In practice it means a named team responsible for how the person actually feels: someone to call between cycles, a plan for pain and breathlessness that does not depend on reaching the oncologist, help with appetite and sleep, and attention to the caretaker, who is usually running on empty by the third line. If the decision is to start another line, that team makes the line more tolerable. If the decision is to stop, the support is already running.

We cover this in more depth in Palliative Care Alongside Immunotherapy, Not Instead of It, which explains what the team does and how to ask for a referral without it being read as giving up.

• Day-to-day function is dropping — how much of the day is spent resting rather than up and about is the single factor that most changes how a later line is tolerated. Ask your oncologist where you now sit on the performance-status scale and what that means for the options.
• Symptoms are not controlled — pain, breathlessness or nausea that is not settling is a reason to bring symptom-focused care forward immediately, whatever is eventually decided about treatment.
• Progression has come quickly through recent lines — disease that has moved through two lines in a few months behaves differently from disease that stayed steady for a year. Ask what that pattern means for what is being proposed next.
• More time is being spent in hospital than at home — count the days over the last two months. Families are often surprised by the answer, and it is a fair thing to weigh against the benefit a further line is expected to give.
• The patient has said they have had enough — this is not something to talk someone out of. It is information, and it belongs in front of the oncology team as clearly as any scan result.

None of these means treatment has to stop. They mean the conversation is due. Stopping Treatment: How Families Reach the Decision walks through how that conversation usually goes.

• If part of the question is whether starting immunotherapy this far along still makes sense at all, Is It Too Late to Start Immunotherapy? answers that directly, including when the honest answer is yes.
• If you want to understand what symptom-focused care actually provides while treatment continues, read Palliative Care Alongside Immunotherapy, Not Instead of It.
• If the conversation in your family has moved toward stopping, Stopping Treatment: How Families Reach the Decision sets out how other families reached it and what happened next.
• For the wider picture — how immunotherapy is delivered, monitored and reviewed at CION — start at the Immunotherapy at CION Cancer Clinics hub.

Weighing this for someone in your own family? Request a free second opinion and a medical oncologist will go through the realistic benefit, the cost and the option of stopping, whichever way you are leaning.